RICHLAND, WASHINGTON – September 16, 2020 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori...
Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a...
WCBS CEO Radio looks at the data that points to Cesium-131 as an effective cancer-fighting treatment option with CEO Lori Woods and an upcoming study that will look at its use in treating head and neck...
Beneath the COVID-19 headlines, WCBS’ CEO Radio talks with Isoray CEO Lori Woods about Cesium-131 internal radiation therapy and making a difference in treating people with...
Expect to hear more about promising treatments like Cesium-131 internal radiation therapy says WCBS’s CEO Radio host Ray Hoffman talking with Isoray CEO Lori Woods about treating cancer during...
Cancer doesn’t stop because of COVID-19 and Isoray CEO Lori Woods says the company took early action to stay ahead of the pandemic. Here’s what she told WCBS’s CEO Radio about protecting access to Cesium-131 brachytherapy....
In the first of a five part series, WCBS’s CEO Radio talks to CEO Lori Woods about how the company moved quickly to meet the challenges of COVID-19 assuring doctors and their patients access to cancer fighting Cesium-131 internal radiation therapy. News-talk radio...
In a recent conversation with Big Biz TV, CEO Lori Woods talked with Big Biz TV about Isoray’s important role in the war on cancer and the difference Cesium-131 internal radiation therapy is making in treating prostate and hard to treat cancers including brain, lung,...
Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection RICHLAND, Wash., June 17, 2020 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE American: ISR) today announced that it has entered into a research grant agreement with the...
RICHLAND, WASHINGTON – June 2, 2020 – Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 (Cesium Blu) internal...
